Advertisement
Document › Details
Biognosys AG. (10/5/21). "Press Release: Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution". Schlieren.
Organisation | Biognosys AG | |
Group | Bruker (Group) | |
Organisation 2 | Society for Immunotherapy of Cancer (SITC) | |
Product | biomarker discovery technology | |
Product 2 | HRM-MS technology (Hyper Reaction Monitoring) | |
Person | Serroen, Yves (Biognosys 202109 Head of Marketing) | |
The new and improved workflow will offer unprecedented depth and quantitative precision, identifying up to 3,000 plasma proteins
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.
The launch will feature a:
• Launch Webinar on November 9th – Plasma Proteomics: The Next Frontier of Biomarker Discovery in the Precision Medicine Era
• Launch Exhibition at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12-14th in Washington, D.C.
The biomarker discovery solution will be offered as a contract research service, designed to help biopharma and academic researchers decode the complexity of biology and unlock true, unbiased discoveries for drug development.
The new and improved workflow will offer unprecedented depth and quantitative precision. The workflow will search the complete plasma proteome to identify up to 3,000 of the most relevant plasma proteins. Measuring on average ten peptides for each identified protein, the research service will provide the deepest ever understanding of the key pathways involved in discovery research.
The workflow can be applied across all biological species and to other biofluids, such as cerebrospinal fluid (CSF) or urine. In addition to the biofluid biomarker discovery service, an improved tissue biomarker discovery service will become available, offering an industry-leading depth of 10,000 proteins.
Both solutions will be based on Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and the latest, optimized LC-MS workflow.
Contact our team to learn more about early access possibilities and pricing.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
Record changed: 2023-06-05 |
Advertisement
More documents for Bruker (Group)
- [1] NanoString Technologies, Inc.. (4/17/24). "Press Release: NanoString Technologies to Be Acquired by Bruker Corporation. Bruker Wins Competitive Auction". Seattle, WA....
- [2] Biognosys AG. (4/4/24). "Press Release: Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research". Zürich & Fremont, CA....
- [3] Bruker Corporation. (1/25/24). "Press Release: Bruker Announces Agreement to Acquire Chemspeed". Basel....
- [4] Bruker Corporation. (1/23/24). "Press Release: Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts". Zürich & Newton, MA....
- [5] Bruker Corporation. (1/3/24). "Press Release: Bruker Acquires Electron Microscopy Company Nion". Billerica, MA....
- [6] Bruker Corporation. (12/26/23). "Form 8-K. Current Report [Acquisition of Elitech Group by Bruker for €870m from PAI Partners] CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest ev...
- [7] Bruker Corporation. (10/4/23). "Press Release: Bruker Announces Majority Investment in MIRO Analytical AG, an Innovator in Compact, Highest-Precision QCL-Based Multi-Gas Analyzers (MGA)". Zürich....
- [8] Bruker Corporation. (10/3/23). "Press Release: Bruker Completes Acquisition of PhenomeX". Billerica, MA....
- [9] Bruker Corporation. (9/18/23). "Press Release: Bruker Introduces Novel 4D-Proteomics timsTOF Capabilities". Busan....
- [10] Bruker Corporation. (8/17/23). "Press Release: Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction". Billerica, MA & Emeryville, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top